CompletedPhase 3

Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients

China388 participantsStarted 2009-04

Plain-language summary

The primary objective of this study is to evaluate the efficacy of quetiapine fumarate extended-release (XR) used as mono-therapy, administered once daily, in the treatment of schizophrenic patient with acute episode.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Schizophrenia diagnosis * Provision of written informed consent before initiation of any study Exclusion Criteria: * AIDS and hepatitis B * History of seizure disorder * Hospitalisation for schizophrenic more than 1 month immediately before enter into study

What they're measuring

Change From Baseline of the Positive and Negative Syndrome Scale (PANSS) Total Score at the End of Treatment at Day 42

Timeframe: Baseline and 6 weeks

Trial details

NCT IDNCT00882518

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2010-07

Results submitted2011-03-07

View on ClinicalTrials.gov More Schizophrenia trials